

COVID-19 Vaccines & Administration Codes											
Revised: July 1, 2023											
Submit claim for administration fee with the appropriate vaccine CPT Code. The administration Code must appear on the detail line prior the vaccine code. (See NOTE Section for additional instructions)											
#	CPT HCPCS	Vaccine Code Description, Dose	Vaccine Administration Code(s)	Labeler Name	Drug Name	Patient's Age	NDC	Max Allow	Max Units/Day	GAMMIS Effective Date (Vaccine)	NOTE
1	91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	0001A (First Dose) 0002A (Second Dose) 0003A (Third Dose) 0004A (Booster Dose)	Pfizer, Inc.	PFIZER-BIONTECH COVID-19 VACC 30MCG/0.3ML Suspension	12 Years & Older	59267-1000-01 59267-1000-02 59267-1000-03	\$0.00 - Vaccine \$40.00 - Admin	1	12/11/2020	Report 91300 with administration codes 0001A, 0002A, 0003A, 0004A
2	91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	0011A (First Dose) 0012A (Second Dose) 0013A (Third Dose)	Moderna, Inc	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	12 Years & Older	80777-0273-10 80777-0273-15 80777-0273-98 80777-0273-99	\$0.00 - Vaccine \$40.00 - Admin	1	12/18/2020	Report 91301 with administration codes 0011A, 0012A, 0013A
3	91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use	0031A (Single Dose) 0034A (Booster Dose)	Janssen	JANSSEN COVID-19 VACCINE 0.5ML Suspension	18 Years & Older	59676-0580-05 59676-0580-15	\$0.00 - Vaccine \$40.00 - Admin	1	2/27/2021	Report 91303 with administration codes 0031A, 0034A
4	91304	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use	0041A (1st Dose) 0042A (2nd Dose)	Novavax	Novavax Covid-19 Vaccine, Adjuvanted	12 Years & Older	80631-1000-01	\$0.00 - Vaccine \$40.00 - Admin	1	7/13/2022	Report 91304 with administration codes 0041A, 0042A, 0044A
			0044A (Booster Dose)			18 Years & Older	80631-1000-01			10/19/2022	
5	91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	0051A (First Dose) 0052A (Second Dose) 0053A (Third Dose) 0054A (Booster Dose)	Pfizer, Inc.	PFIZER-BIONT COVID-19 VAC-TRIS 30MCG/0.3ML Suspension	12 Years & Older	59267-1025-01 59267-1025-02 59267-1025-03 59267-1025-04	\$0.00 - Vaccine \$40.00 - Admin	1	11/1/2021	Report 91305 with administration codes 0051A, 0052A, 0053A, 0054A
6	91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	0064A (Booster Dose)	Moderna	MODERNA COVID-19 VACCINE 100MCG/0.5ML Solution	18 Years & Older	80777-0273-10 80777-0273-15 80777-0273-98 80777-0273-99	\$0.00 - Vaccine \$40.00 - Admin	1	10/20/2021	Report 91306 with administration code 0064A
7	91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	0071A (First Dose) 0072A (Second Dose) 0073A (Third Dose) 0074A (Booster Dose)	Pfizer, Inc.	PFIZER COVID-19 VAC-TRIS 5-11Y 10MCG/0.2ML Suspension	5-11 Years Old	59267-1055-01 59267-1055-02 59267-1055-04	\$0.00 - Vaccine \$40.00 - Admin	1	10/29/2021	Report 91307 with administration codes 0071A, 0072A
8	91308	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	0081A (1st Dose) 0082A (2nd Dose) 0083A (3rd Dose)	Pfizer, Inc.	Pfizer-BioNTech Covid-19 Pediatric Vaccine	6 Months - 4 Years	59267-0078-01 59267-0078-04	\$0.00 - Vaccine \$40.00 - Admin	1	6/17/2022	Report 91308 with administration codes 0081A, 0082A, 0083A
9	91309	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	0091A (1st Dose) 0092A (2nd Dose) 0093A (3rd Dose)	Moderna, Inc	Moderna COVID-19 Vaccine	6 - 11 Years	80777-0275-05	\$0.00 - Vaccine \$40.00 - Admin	1	6/17/2022	Report 91309 with administration codes 0091A, 0092A, 0093A, 0094A
			0094A (Booster)			18 Years & older				3/29/2022	
10	91311	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	0111A (1st Dose) 0112A (2nd Dose) 0113A (3rd Dose)	Moderna, Inc	Moderna COVID -19 Vaccine	6 Months - 5 Years	80777 -0279 -05	\$0.00 - Vaccine \$40.00 - Admin	1	6/17/2022	Report 91311 with administration codes 0111A, 0112A, 0113A
11	91312	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	0124A (Booster)	Pfizer, Inc.	Pfizer-BioNTech COVID-19 Bivalent	12 Years & older	59267-0304-01 59267-1404-01	\$0.00 - Vaccine \$40.00 - Admin	1	8/31/2022	Report 91312 with administration code 00124A
12	91313	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	0134A (Booster)	Moderna, Inc	Moderna COVID-19 Vaccine, Bivalent Product	18 Years & older	80777 -0282 -05	\$0.00 - Vaccine \$40.00 - Admin	1	8/31/2022	Report 91313 with administration code 00134A
13	91314	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	0144A (Booster)	Moderna, Inc	Moderna COVID -19 Vaccine, Bivalent	6 - 11 Years	80777 -0282 -05	\$0.00 - Vaccine \$40.00 - Admin	1	8/31/2022	Report 91314 with administration code 00144A
14	91315	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	0154A (Booster)	Pfizer, Inc.	Pfizer-BioNTech COVID-19 Bivale	5 - 11 Years	59267-0565-01	\$0.00 - Vaccine \$40.00 - Admin	1	10/12/2022	Report 91315 with administration code 00154A
15	91316	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use	0164A (Booster)	Moderna, Inc	Moderna COVID -19 Vaccine, Bivalent	6 months through 5 years	80777 -0283 -02	\$0.00 - Vaccine \$40.00 - Admin	1	12/8/2022	Report 91316 with administration code 00164A
16	91317	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	00173A (3rd Dose) 00174A (Booster)	Pfizer, Inc.	Pfizer -BioNTech COVID -19 Bivalen	6 months through 4 years	59267 -0609 -01	\$0.00 - Vaccine \$40.00 - Admin	1	12/8/2022	Report 91317 with administration code 00173A & 00174A
17	M0201	Covid-19 vaccine administration inside a patient's home: reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home	N/A	N/A	N/A	n	N/A	\$35.50	1	6/8/2021	Report M0201 with any combination of vaccine & administration code

COVID-19 Monoclonal Antibodies & Administration Codes

Revised: July 1, 2023

Submit claim for administration fee with the appropriate Monoclonal Antibody HCPCS. The administration code must appear on the claim detail line prior the code for the Monoclonal Antibodies (See NOTE Section for additional instructions)

#	HCPCS	CPT/HCPCS Name, Description, Dose	Labeler Name	Drug Name	NDC	Max Allow	Max Units/Day	GAMMIS Effective Date (Monoclonal...)	NOTE
1	Q0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg	Astra Zeneca	EVUSHELD 150-150MG/1.5ML Solution	00310-1061-01 00310-7442-02 00310-8895-01	\$0.00	1	12/8/2021	Report Q0220 with administration codes M0220, M0221
2	Q0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg	AstraZeneca	Tixagev and cilgav, 600mg	00310-1061-01 00310-7442-02 00310-8895-01	\$0.00	1	2/24/2022	Report Q0221 with administration codes M0220, M0221
3	M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	Astra Zeneca	N/A	N/A	\$120.00	1	12/8/2021	Report M0220 with Q0220 & Q0221
4	M0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	Astra Zeneca	N/A	N/A	\$200.00	1	12/8/2021	Report M0221 with Q0220 & Q0221 for home administration
5	Q0222	Bebtelovimab, 175 mg	Eli Lilly	BEBTELOVIMA	00002-7589-01	\$0.00	1	2/11/2022	Report Q0222 with administration codes M0222, M0223
6	M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	Eli Lilly	N/A	N/A	\$280.00	1	2/11/2022	Report M0222 with Q0222
7	M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	Eli Lilly	N/A	N/A	\$440.00	1	2/11/2022	Report M0223 with Q0222
8	Q0240	Casirivimab and Imdevimab, 600 mg	Regeneron	CASIRIVIMAB 300MG/2.5ML Solution	61755-0026-00	\$0.00	1	7/30/2021	Report Q0240 with administration codes M0240, M0241
	Q0240	Casirivimab and Imdevimab, 600 mg	Regeneron	CASIRIVIMAB 300MG/2.5ML Solution	61755-0026-01	\$0.00	1	7/30/2021	Report Q0240 with administration codes M0240, M0241
	Q0240	Casirivimab and Imdevimab, 600 mg	Regeneron	IMDEVIMAB 300MG/2.5ML Solution	61755-0027-00	\$0.00	1	7/30/2021	Report Q0240 with administration codes M0240, M0241
	Q0240	Casirivimab and Imdevimab, 600 mg	Regeneron	IMDEVIMAB 300MG/2.5ML Solution	61755-0027-01	\$0.00	1	7/30/2021	Report Q0240 with administration codes M0240, M0241
9	M0240	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses	Regeneron	N/A	N/A	\$360.00	1	6/8/2021	Report M0240 with Q0240
10	M0241	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses	Regeneron	N/A	N/A	\$600.00	1	7/30/2021	Report M0241 with Q0240 for home/residence administration
11	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	CASIRIVIMAB 1200MG Solution	61755-0024-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	IMDEVIMAB 1200MG Solution	61755-0025-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	CASIRIVIMAB 300MG/2.5ML Solution	61755-0026-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	IMDEVIMAB 300MG/2.5ML Solution	61755-0027-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 1200MG/1200MG Solution	61755-0035-02	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 1200MG/1200MG Solution	61755-0036-08	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244

COVID-19 Monoclonal Antibodies & Administration Codes									
Revised: July 1, 2023									
Submit claim for administration fee with the appropriate Monoclonal Antibody HCPCS. The administration code must appear on the claim detail line prior the code for the Monoclonal Antibodies (See NOTE Section for additional instructions)									
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 1200MG/1200MG Solution	61755-0037-05	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 1200MG/1200MG Solution	61755-0038-05	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 600-600MG/10ML Solution	61755-0039-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 120MG/ML;120MG/ML Solution	61755-0042-02	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 120MG/ML;120MG/ML Solution	61755-0045-02	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
12	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	CASIRIVIMAB 300MG/2.5ML Solution	61755-0026-01	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	IMDEVIMAB 300MG/2.5ML Solution	61755-0027-01	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	REGEN-COV 600-600MG/10ML Solution	61755-0039-01	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	REGEN-COV 120MG/ML;120MG/ML Solution	61755-0042-02	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	REGEN-COV 120MG/ML;120MG/ML Solution	61755-0045-02	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
13	M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	Regeneron	N/A	N/A	\$360.00	1	12/1/2020	Report M0243 with Q0243/Q0244
14	M0244	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	Regeneron	N/A	N/A	\$600.00	1	5/6/2021	Report M0244 with Q0243 as well as Q0244 for home/residence administration
15	Q0245	Bamlanivimab and Etesevimab, 2100 mg	Eli Lilly	BAMLANIVIMAB 700MG/20ML Solution	00002-7910-01	\$0.00	1	2/9/2021	Report Q0245 with administration codes M0245, M0246
	Q0245	Bamlanivimab and Etesevimab, 2100 mg	Eli Lilly	ETESEVIMAB 35MG/ML Solution	00002-7950-01	\$0.00	1	2/9/2021	Report Q0245 with administration codes M0245, M0246
16	M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	Eli Lilly	N/A	N/A	\$360.00	1	2/9/2021	Report M0245 with Q0245
17	M0246	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	Eli Lilly	N/A	N/A	\$600.00		5/6/2021	Report M0246 with Q0245 for home/residence administration
18	Q0247	Sotrovimab, 500 mg	GSK	SOTROVIMAB 500MG/8ML Solution	00173-0901-86	\$0.00	1	5/26/2021	Report Q0247 with administration codes M0247, M0248
19	M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	GSK	N/A	N/A	\$360.00		5/26/2021	Report M0247 with Q0247
20	M0248	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	GSK	N/A	N/A	\$600.00		5/26/2021	Report M0248 with Q0247 for home/residence administration
21	Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	Genentech	ACTEMRA 20MG/ML Solution	50242-0135-01	\$6.57	800	6/24/2021	Report Q0249 with administration codes M0249, M0250
	Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	Genentech	ACTEMRA 200MG/10ML Solution	50242-0136-01	\$6.57	800	6/24/2021	Report Q0249 with administration codes M0249, M0250
	Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	Genentech	ACTEMRA 400MG/20ML Solution	50242-0137-01	\$6.57	800	6/24/2021	Report Q0249 with administration codes M0249, M0250
22	M0249	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose	Genentech	N/A	N/A	\$360.00	1	6/24/2021	Report M0249 with Q0294 - 1st dose
23	M0250	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose	Genentech	N/A	N/A	\$360.00	1	6/24/2021	Report M0250 with Q0294 - 2nd dose